| 4.6038 0.154 (3.46%) | 06-15 09:49 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.68 | 1-year : | 6.64 |
| Resists | First : | 4.86 | Second : | 5.68 |
| Pivot price | 4.07 |
|||
| Supports | First : | 4.02 | Second : | 3.5 |
| MAs | MA(5) : | 4.03 |
MA(20) : | 4.11  |
| MA(100) : | 4.07 |
MA(250) : | 3.61 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 65.9 |
D(3) : | 43.2 |
| RSI | RSI(14): 58.5 |
|||
| 52-week | High : | 5.46 | Low : | 1.37 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PGEN ] has closed below upper band by 21.2%. Bollinger Bands are 37.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.71 - 4.74 | 4.74 - 4.76 |
| Low: | 4.36 - 4.38 | 4.38 - 4.4 |
| Close: | 4.41 - 4.45 | 4.45 - 4.48 |
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Mon, 15 Jun 2026
PAPZIMEOS keeps 83% of RRP complete responders surgery-free 3+ years - Stock Titan
Fri, 12 Jun 2026
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares? - Yahoo Finance
Thu, 11 Jun 2026
27,000 US patients, one new therapy: inside RRP Awareness Day - Stock Titan
Fri, 05 Jun 2026
PGEN News | PRECIGEN INC (NASDAQ:PGEN) - ChartMill
Mon, 01 Jun 2026
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Wed, 27 May 2026
Precigen (PGEN) CLO converts 62,500 RSUs into common shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -90 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 3.5651e+008 (%) |
| Held by Institutions | 1.8946e+008 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.118e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.22 |
| Profit Margin | 0 % |
| Operating Margin | -25.8 % |
| Return on Assets (ttm) | -42.1 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 3.159e+007 % |
| Gross Profit (p.s.) | -0.11 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | -8.633e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -3.68 |
| Price to Sales | 162.7 |
| Price to Cash Flow | 0 |
| Dividend | 4.025e+007 |
| Forward Dividend | 3.977e+007 |
| Dividend Yield | 904494000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|